Tasigna vs. Sprycel

Now that Novartis’s Tasigna (nilotinib), another leukemia drug, is now under Korea’s health insurance coverage from July 1 for the treatment of first-line chronic myeloid leukemia, the race has officially begun for two second-generation BCR-ABL kinase inhibitors to supplant the venerable market-leader, Novartis' Gleevec.

Tasigna is a tyrosine kinase inhibitor approved for the treatment of ad...